Vaccine for triple-negative breast cancer produces ‘exciting’ results in early testing

Preliminary results of a phase 1 trial for a novel vaccine that could eventually prevent triple-negative breast cancer exceeded expectations, based on data presented at San Antonio Breast Cancer Symposium.
Researchers at Cleveland Clinic tested the vaccine on 16 women and 75% showed an immunologic response to the drug, which is based on the “retired protein hypothesis” developed by Vincent Tuohy, PhD, immunologist at Cleveland Clinic’s Lerner Research Institute, who died in January.
Study investigators also determined a safe dose of the vaccine with no adverse reactions but

Leave a Comment

Your email address will not be published. Required fields are marked *

Shopping Cart
This website uses cookies and asks your personal data to enhance your browsing experience.